6.6
Adrenerge agonisten: indirect werkende middelen
Indirect werkende adrenerge agonisten versterken de effecten van endogene catecholamines via verschillende mechanismen zonder rechtstreeks te binden a…
Indirect-acting adrenergic agonists enhance the effect of endogenous catecholamines through varied mechanisms.
Agonists such as amphetamine and tyramine are termed "displacers" as they induce catecholamine release by depleting their stores from the synaptic vesicle.
They resemble noradrenaline but lack a catechol moiety. Due to this resemblance, they are actively transported into synaptic vessels and, eventually, replace noradrenaline.
The cytosolic noradrenaline is then exchanged for another displacer molecule and released to act on postsynaptic adrenoceptors.
Another mechanism involves catecholamine reuptake inhibition. Cocaine blocks the transporter involved in catecholamine reuptake, thus potentiating sympathomimetic action.
Additionally, selegiline—a MAO inhibitor, and entacapone —a COMT inhibitor, are indirect-acting sympathomimetics as they prevent metabolism and subsequent excretion of circulating catecholamines.
Indirect-acting agonists like cocaine and amphetamine are often abused due to their central effects, like euphoria resulting from dopamine and serotonin release.
View the full transcript and gain access to JoVE Core videos
Q1: How do displacer drugs like amphetamine and tyramine work as indirect-acting agonists?
Displacers resemble noradrenaline but lack a catechol moiety, allowing active transport into synaptic vesicles. Once inside, they replace stored noradrenaline, which is then released to act on postsynaptic adrenoceptors. This mechanism enhances sympathomimetic effects without directly binding to receptors. Amphetamine and tyramine exemplify this displacement strategy.
Q2: What is the mechanism by which cocaine acts as an indirect-acting sympathomimetic?
Cocaine blocks the transporter responsible for catecholamine reuptake, preventing noradrenaline and dopamine from being removed from the synaptic cleft. This potentiates sympathomimetic action by prolonging neurotransmitter availability at adrenoceptors. As a local anesthetic with reuptake-inhibiting properties, cocaine produces both peripheral and central nervous system effects.
Q3: How do MAO inhibitors and COMT inhibitors enhance catecholamine effects?
MAO inhibitors like selegiline and COMT inhibitors like entacapone prevent the breakdown and excretion of circulating catecholamines. By blocking these metabolic pathways, these enzyme inhibitors increase catecholamine concentration and duration of action, indirectly potentiating sympathomimetic responses without directly activating adrenoceptors.
Q4: Why do amphetamine and cocaine have abuse potential despite their pharmacological differences?
Both amphetamine and cocaine stimulate central nervous system effects, particularly dopamine and serotonin release, producing euphoria and reward sensations. Although they use different mechanisms—displacement versus reuptake inhibition—both drugs enhance monoamine availability in the brain, driving their addictive potential and abuse liability.
Q5: What structural feature distinguishes displacer agonists from direct-acting adrenergic agonists?
Displacer agonists like amphetamine and tyramine lack a catechol moiety present in noradrenaline and direct-acting agents. This structural difference enables their active transport into synaptic vesicles, improves oral bioavailability, and enhances central nervous system penetration. The absence of the catechol group is essential to their displacement mechanism.
Q6: How does tyramine in fermented foods interact with MAO inhibitor medications?
Tyramine, a displacer agonist found in fermented foods, mimics sympathetic responses by releasing stored catecholamines. When individuals take MAO inhibitors, tyramine metabolism is blocked, causing excessive accumulation and potentiation of sympathomimetic effects. This interaction can produce dangerous hypertensive responses, making dietary tyramine restriction important during MAO inhibitor therapy.
Q7: What distinguishes indirect-acting agonists from direct-acting agents in their mechanism of action?
Indirect-acting agonists enhance endogenous catecholamine effects through displacement, reuptake inhibition, or enzyme inhibition rather than directly binding to adrenoceptors. Direct-acting agents bind directly to adrenoceptors to produce their effects. Indirect agents potentiate existing neurotransmitter activity, while direct agents independently activate receptors.